A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial

Principal Investigator

Eric Anderson

Study Purpose

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Medical Condition(s)

Advanced or Metastatic Non-Small Cell Lung Cancer

Eligibility Criteria

Female or male ≥18 years of age
Confirmed diagnosis of unresectable Stage IIIb (advanced) or Stage IV (metastatic) NSCLC

Age Range

18 - 120

Healthy Volunteers Needed


Duration of Participation

Your length in time in the study, including the screening, treatment, and follow-up periods, will be about 4-6 years.

Minors Included



Knight Cancer Institute Clinical Trials
503 494-1080


F. Hoffmann-La Roche Ltd

Recruitment End


Compensation Provided


Go Back